In May, Guangzhou is bustling with the surging tides of the Pearl River. On May 23, 2025, the 90th National Pharmaceutical Fair (PHARMCHINA)—a three-day event—came to a close at the China Import and Export Fair Complex in Guangzhou. This year’s fair featured over 2,000 booths and more than 30 conference activities, bringing together numerous well-known domestic and international companies. Concurrent with the fair, over 70 conferences, forums, and events were held, attracting more than 100,000 industry professionals who exchanged ideas and discussed hot topics, collectively gaining insights into the future of the industry. As one of the most influential events in China’s pharmaceutical sector, NORTHLAND made its debut at the fair with its star product, "Donaperminogene Seltoplasmid Ingection." With its unique status as a Class 1 innovative drug and a gene therapy product, NORTHLAND attracted many visitors and agents eager to learn more and engage in discussions.

 “Sedominji” Debuts at the Exhibition—Class 1 Innovative Drug Attracts Attention

The Donaperminogene Seltoplasmid Ingection is a gene therapy drug independently developed by NORTHLAND, primarily indicated for the treatment of severe lower-limb ischemic diseases. The product was submitted for new drug approval in July 2024 and is currently undergoing the review process. At this exhibition, the company set up a dedicated booth for Cedomin, providing visitors with a clear and intuitive presentation of the drug’s mechanism of action, clinical study results, and disease overview. Meanwhile, the company dispatched a professional team—including members from marketing, sales, and medical departments—led by the vice president. During the exhibition, the team demonstrated enthusiastic work spirit, profound product knowledge, and sincere collaborative attitudes, carefully introducing the company and its products to visitors, answering questions individually, and engaging in exchanges with industry professionals about the clinical diagnosis and treatment of gene therapy and lower-limb ischemic diseases. This helped deepen customers’ understanding of the company and the product, showcasing the excellent professionalism of NORTHLAND’s employees. Throughout the exhibition, the company’s booth was bustling with visitors coming and going continuously. Over the three-day period, the booth welcomed more than 300 visitors. Everyone diligently collected feedback from distributors regarding the product and potential collaborations, thoroughly enjoying the experience. Through the exhibition, the company also gained clearer insights into its sales strategy and further strengthened its confidence in the product’s market launch.

 The company’s vice president delivered a keynote speech, exploring the commercialization pathways for innovative drugs.

At the inaugural China Pharmaceutical Ecosystem Restructuring Forum held concurrently with the exhibition, Zhao Lei, Vice President of the company, was invited to deliver a keynote speech titled “Reflections on the Commercialization Path and Collaboration Mechanisms for Gene Therapy Drugs.” The venue was packed, with over a hundred industry professionals in attendance. In his speech, Mr. Zhao analyzed the opportunities and challenges facing the CGT sector from multiple perspectives, including current global and domestic development trends, policy orientations, and pharmaceutical companies’ practices in commercializing innovative drugs. He also shared the company’s journey in developing innovative drugs, highlighting Sedominji’s innovative features and the results of its Phase III clinical trials. Furthermore, he engaged in discussions with the attendees regarding Sedominji’s commercialization strategy. During the conference, Mr. Zhao officially released information on Sedominji’s recruitment of distributors, extending an open invitation to agents nationwide to explore cooperation opportunities. Following the conference, numerous agents proactively visited the company’s booth to engage in detailed discussions about the specifics of distributing Sedominji, demonstrating strong interest in partnering with the company to distribute this innovative product.

 We sincerely invite agents from across the country to jointly explore new blue ocean markets.

This pharmaceutical fair not only provided NORTHLAND with a platform to showcase our products and strengths, but also enabled us to forge closer ties with industry partners, enhance communication and interaction, and seize valuable collaboration opportunities. Taking the 90th Pharmaceutical Fair as an opportunity, our company is now officially launching the nationwide recruitment of agents for Sedominji. We will adopt a “self-operated + provincial-level agency” model and sincerely invite agents from across the country to jointly explore the promising market for Donaperminogene Seltoplasmid Ingectioninjection—a Class 1 biological product. The company will offer partners comprehensive market training, academic promotion resources, and digital marketing support. After the fair concludes, we will meticulously analyze customer needs and engage in in-depth discussions with prospective partners to facilitate the implementation of collaborations. We also welcome more agents to reach out and learn more—let’s work together to accelerate the launch of Donaperminogene Seltoplasmid Ingectionand jointly bring new options for the clinical diagnosis and treatment of lower-limb ischemic diseases, offering fresh hope to patients suffering from these conditions.